熱門資訊> 正文

Humacyte因Symvess出售给军事治疗机构而上涨

2025-07-24 02:30

Humacyte (NASDAQ:HUMA) shares jumped on Wednesday following the announcement of the first sale of Symvess, its vascular repair product, to a U.S. Military Treatment Facility.
The sale comes after the U.S. Defense Logistics Agency recently approved the ECAT listing for Symvess.
The shares of the company are up 16%.
ECAT is an internet solution through which commercial catalogs of multiple manufacturers and distributors are available at discounted prices for the U.S. Department of Defense and other federal agencies.

More on Humacyte

Humacyte: Revenue Ramp From Symvess Incoming
Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey
Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
Humacyte jumps as DoD issues ECAT listing approval for Symvess
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。